Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.

@article{Jarnagin2009RegionalCF,
  title={Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.},
  author={William R. Jarnagin and Lauren H Schwartz and David H. Gultekin and Mithat G{\"o}nen and D. Haviland and Jingu Shia and Michael Ian D'Angelica and Yaou Fong and R Dematteo and Anissa Tse and Leslie Harold Blumgart and Naomi Kemeny},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2009},
  volume={20 9},
  pages={1589-95}
}
BACKGROUND This study reports the results of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (dex) in patients with unresectable intrahepatic cholangiocarcinoma (ICC) or hepatocellular carcinoma (HCC) and investigates dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) assessment of tumor vascularity as a biomarker of outcome. PATIENTS AND METHODS Thirty-four unresectable patients (26 ICC and eight HCC) were treated with HAI FUDR/dex. Radiologic dynamic… CONTINUE READING
47 Citations
45 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 45 references

Sorafenib improved survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial)

  • JM Llovet
  • J Clin Oncol 2007 ASCO Annual Meeting Proceedings…
  • 2007

Similar Papers

Loading similar papers…